ChiCTR2400082124 版本V1.0 版本创建时间2024/03/21 11:07:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400082124 

最近更新日期:

Date of Last Refreshed on:

2024-03-21 11:07:03 

注册时间:

Date of Registration:

2024-03-21 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

超声引导下针刀治疗腕管综合征的安全及临床疗效

Public title:

The safety and clinical efficacy of ultrasound-guided acupotomy therapy for carpal tunnel syndrome

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下针刀治疗腕管综合征的安全及临床疗效

Scientific title:

The safety and clinical efficacy of ultrasound-guided acupotomy therapy for carpal tunnel syndrome

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何宁宁 

研究负责人:

何宁宁 

Applicant:

He Ningning 

Study leader:

He Ningning 

申请注册联系人电话:

Applicant telephone:

+86 152 9551 9657

研究负责人电话:

Study leader's
telephone:

+86 152 9551 9657

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

506092567@qq.com

研究负责人电子邮件:

Study leader's E-mail:

506092567@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区汉中路155号

研究负责人通讯地址:

江苏省南京市秦淮区汉中路155号

Applicant address:

No. 155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

Study leader's address:

No. 155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省中医院

Applicant's institution:

Jiangsu Province Hospital of TCM

研究负责人所在单位:

江苏省中医院

Affiliation of the Leader:

Jiangsu Province Hospital of TCM

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2023NL-076-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京中医药大学大学附属医院(江苏省中医院)伦理委员会

Name of the ethic committee:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023-05-09 00:00:00

伦理委员会联系人:

王卯

Contact Name of the ethic committee:

Wang Mao

伦理委员会联系地址:

江苏省南京市秦淮区汉中路155号

Contact Address of the ethic committee:

No. 155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 135 0514 1991

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中医院

Primary sponsor:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

江苏省南京市秦淮区汉中路155号

Primary sponsor's address:

155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

CHINA

Province:

Jiangsu Province

City:

单位(医院):

江苏省中医院

具体地址:

江苏省南京市秦淮区汉中路155号

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Address:

155 Hanzhong Road, Qinhuai District, Nanjing City, Jiangsu Province

经费或物资来源:

江苏省中医院

Source(s) of funding:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

研究疾病:

腕管综合征  

Target disease:

Carpal tunnel syndrome

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

单病例随机对照研究 

Study design:

N of 1 Trial 

研究目的:

评价肌骨超声引导下针刀治疗腕管综合征的临床疗效和安全性;进一步探讨针刀临床安全术式,为针刀治疗腕管综合征临床及针刀可视化技术的临床运用提供理论依据。  

Objectives of Study:

To evaluate the clinical efficacy and safety of musculoskeletal ultrasound-guided needle-knife treatment for carpal tunnel syndrome. To further explore the clinical safety of acupotomy and provide theoretical basis for the clinical treatment of carpal tunnel syndrome and the clinical application of acupotomy visualization technology.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 符合腕管综合征诊断标准。2. 年龄在18~65岁之间,性别不限。3. 慢性起病,病程在1个月--2年之内。4. 知情同意,志愿受试。获得知情同意书过程应符合GCP规定。

Inclusion criteria

1. Meet the diagnostic criteria for carpal tunnel syndrome. 2. Age between 18 and 65 years old, regardless of gender. 3. Chronic onset, course of disease within 1 month -2 years. 4. Give informed consent and volunteer for the test. The process of obtaining informed consent shall comply with GCP regulations.

排除标准:

1.不符合上述诊断标准和纳入标准; 2.已经出现外科手术治疗指征的重度腕管综合征患者; 3.严重内脏病发作期及严重心、肝、肾功能损害者: 4.严重的骨质疏松症、骨结核病及晚期肿瘤患者; 5.严重糖尿病患者、药物过敏(如曲安奈德、利多卡因)者; 6.有自发性出血倾向及凝血功能障碍(如血友病、血小板减少症)者; 7.正在或长期服用抗凝血药物(如阿司匹林)者; 8.正在接受其他相关治疗,可能影响本研究观测指标; 9.不能配合针刀治疗者; 10.精神病患者、严重认知功能障碍不合作者。

Exclusion criteria:

1. Does not meet the above diagnostic criteria and inclusion criteria; 2. Patients with severe carpal tunnel syndrome who have shown signs of surgical treatment; 3. Severe visceral disease and severe heart, liver and kidney damage: 4. Patients with severe osteoporosis, bone tuberculosis and advanced tumors; 5. Patients with severe diabetes and drug allergies (such as triamcinolone and lidocaine); 6. Spontaneous bleeding tendency and coagulation dysfunction (such as hemophilia, thrombocytopenia); 7. People who are taking or long-term taking anticoagulant drugs (such as aspirin); 8. Is receiving other related treatment, which may affect the observational indicators of this study; 9. Patients who cannot cooperate with acupotomy treatment; 10. Psychopaths and severe cognitive dysfunction are not suitable for the author.

研究实施时间:

Study execute time:

From 2023-04-01 00:00:00 To 2025-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-01 00:00:00 To 2024-12-01 00:00:00

干预措施:

Interventions:

组别:

可视化组

样本量:

24

Group:

Visual group

Sample size:

干预措施:

盲试组采用传统针刀疗法,可视化组在此基础上采用超声引导,观察并分析两组治疗前后的临床疗效、并发症发生率、VAS值、Michigan手功能评分、电生理指标(CMAP、DML、SNAP、SCV值)、超声影像学(CSA、△-CSA、R-CSA值)、腕横韧带厚度的变化等指标。

干预措施代码:

Intervention:

The blind trial group was treated with traditional needle-knife therapy, and the visualization group was guided by ultrasound. The clinical efficacy, complication rate, VAS value, Michigan hand function score, electrophysiological indexes (CMAP, DML, SNAP, SCV), ultrasonic imaging (CSA, △-CSA, R-CSA), transverse ligament thickness changes before and after treatment of the two groups were observed and analyzed.

Intervention code:

组别:

盲视组

样本量:

24

Group:

Blind group

Sample size:

干预措施:

盲试组采用传统针刀疗法,可视化组在此基础上采用超声引导,观察并分析两组治疗前后的临床疗效、并发症发生率、VAS值、Michigan手功能评分、电生理指标(CMAP、DML、SNAP、SCV值)、超声影像学(CSA、△-CSA、R-CSA值)、腕横韧带厚度的变化等指标。

干预措施代码:

Intervention:

The blind trial group was treated with traditional needle-knife therapy, and the visualization group was guided by ultrasound. The clinical efficacy, complication rate, VAS value, Michigan hand function score, electrophysiological indexes (CMAP, DML, SNAP, SCV), ultrasonic imaging (CSA, △-CSA, R-CSA), transverse ligament thickness changes before and after treatment of the two groups were observed and analyzed.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

CHINA

Province:

Jiangsu Province

City:

单位(医院):

江苏省中医院 

单位级别:

三甲 

Institution
hospital:

Jiangsu Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

trimethylate

测量指标:

Outcomes:

指标中文名:

临床疗效

指标类型:

主要指标

Outcome:

Clinical effect

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症发生率

指标类型:

附加指标

Outcome:

Complication rate

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS值

指标类型:

主要指标

Outcome:

Visual analogue scale, VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Michigan手功能评分

指标类型:

主要指标

Outcome:

Michigan score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

电生理指标(CMAP、DML、SNAP、SCV值)

指标类型:

次要指标

Outcome:

Electrophysiological index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

超声影像学(CSA、△-CSA、R-CSA值)

指标类型:

次要指标

Outcome:

Ultrasonic imaging

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腕横韧带厚度的变化

指标类型:

次要指标

Outcome:

Changes in the thickness of the transverse ligament of the wrist

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表法(1.编码员将总体中的48例研究对象进行统一编号, 并充分混合。2.确定抽样起点:根据需要或意愿,在表上选择一数字编号,由该数字决定抽样的起点。3.确定抽样顺序:根据需要或意愿, 选择一定顺序方向,使用该种顺序方向进行抽取。4.录取号码:根据抽样起点和抽样顺序进行依次录取号码,直至录取到所需抽取的样本数满为止。)

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method(1. The coders numbered 48 subjects in the population and mixed them fully. 2. Determine the starting point: according to the need or desire to select a number on the table, the number decided by the starting point of the sampling. 3. Determine the order of sampling: according to the need or desire, select a certain order direction, using the Order of the direction of the sampling. Four. Admission number: according to the starting point of the sampling and the sampling order for admission number, until admission to the required number of samples to be taken until the full)

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台 IPD(http://www.medresman.org.cn)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan IPD (http://www.medresman.org.cn) .

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集管理写用电子病历记录表进行采集,暂不考虑使用EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection management is carried out by using electronic medical record form, and EDC is not considered for the time being

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-03-21 11:07:03